<DOC>
	<DOCNO>NCT01475409</DOCNO>
	<brief_summary>The screening latent tuberculosis infection ( LTBI ) prior onset anti-tumor necrosis factor therapy , well watchful monitoring treatment , strongly recommend . Tuberculin skin test ( TST ) , universally use purpose , lack sensitivity specificity . The novel screening tool , include QuantiFERON-TB Gold In-Tube ( QFT-GIT ) , show high specificity compare TST , feasibility set immunosuppression remain unclear . Aims study investigate performance QFT-GIT agreement TST patient await anti-tumor necrosis factor ( TNF ) therapy , evaluate usefulness serial QFT-GIT treatment biologics ass whether dynamic change interferon ( IFN ) -gamma level may helpful identify reactivation LTBI case newly acquire tuberculosis .</brief_summary>
	<brief_title>A Study Changes IFN-gamma Levels Following Anti-TNF Treatment Patients Undergoing Serial QuantiFERON-TB Gold In-Tube</brief_title>
	<detailed_description />
	<mesh_term>Rheumatic Diseases</mesh_term>
	<mesh_term>Collagen Diseases</mesh_term>
	<mesh_term>Interferon-gamma</mesh_term>
	<criteria>clinical diagnosis inflammatory rheumatic disease patient candidate antiTNF treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>anti-TNF</keyword>
	<keyword>tuberculosis</keyword>
	<keyword>QuantiFERON-TB Gold In-Tube</keyword>
	<keyword>tuberculin skin test</keyword>
	<keyword>rheumatoid arthritis</keyword>
	<keyword>spondyloarthritis</keyword>
</DOC>